2022年10月4日,

印第安纳州申请First-In-Class临床候选人针对2023 10月04,2022年东部时间上午08:07帕洛阿尔托,加州——(业务线)端点健康,Inc . Precision-FirstTM疗法公司今天公布了其最新的精密免疫学项目针对炎症介导的组织因子(TF)端依赖细胞内信号。该公司将利用其精度AI平台来识别潜在的反应项目的主要资产,EP004,一个first-in-class anti-TF单克隆抗体(mAb),跨多个自身免疫性迹象。发展与创新精密AI平台这种first-in-class治疗大范围的迹象可能会改变患者免疫介导的炎症性疾病的治疗范例(醯亚氨)。而不是使用传统的“一刀切”疗法,这部小说精密医学策略可以使卫生保健提供者设计治疗计划优化为每个病人的独特的生物学。组织因子一直是历史上开发中央生物目标和先天免疫的基本中介活动和凝固。这是司机的炎症、趋化性和跨广泛的醯亚氨止血,包括溃疡性结肠炎、克罗恩病、红斑狼疮、和某些vasculitides。组织因子代表一个有吸引力的目标疾病修饰治疗旨在减少促炎细胞因子和趋化因子。EP004(原名ICON-4)是一个first-in-class anti-TF马伯独特的旨在减少炎症的选择性抑制TF-dependent胞内信号,同时避免与hemostasis-related TF通路的函数。EP004目前完成IND-enabling研究,公司预计2023年印第安纳州提交。这个新推出的精密免疫学项目通过端点健康最近收购的标志性的疗法,preclinical-stage生物技术公司开发选择性治疗包括ICON4(现在EP004)解决TF-mediated信号。 "Using our precision AI platform, we could see the great potential for tissue factor, not only as a therapeutic target, but as an opportunity to develop a highly differentiated precision therapy across a wide range of indications where patients have significant unmet medical need. The opportunity to bring the incredible work of the Iconic Therapeutics team into the clinic for autoimmune diseases represents a key step towards our mission of getting the best therapy to each patient, based on their specific biological need," said Jason Springs, CEO and Co-Founder of Endpoint Health. "As an investor, drug developer and CEO, I’ve seen how precision approaches to drug development have transformed oncology and genetically defined diseases. We’re at the cusp of a similar revolution in immunology where there is a huge need for both new therapies and a better way to target them to the right patient. Combining our novel pipeline with Endpoint Health’s unique precision capability is a rare opportunity to solve for both needs," said Bill Greene, CEO of Iconic Therapeutics. This new program unveiling closely follows Endpoint Health’s appointment of Ransi Somaratne as Chief Medical Officer and a Series A financing round of $52 million, which closed earlier this year with commitments from major institutional investors, such as Mayfield, Humboldt Fund, AME Cloud Ventures, Global Health Investment Corporation (GHIC), and others. About Endpoint Health Endpoint Health is a Precision-FirstTM therapeutics company dedicated to addressing unmet needs in immune-mediated chronic and acute diseases. We leverage our proprietary artificial intelligence (AI) platform and combine companion diagnostics with therapeutics to develop precision therapies. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease. For more information, visit www.endpointhealth.com . Follow us on Social Media: LinkedIn , Twitter About Iconic Therapeutics Iconic Therapeutics, incorporated in 2002, a wholly owned subsidiary of Endpoint Health, developed a portfolio of proprietary molecules that bind to and antagonize TF-mediated signaling. Their unique approach to modulating TF-mediated regulation of multiple cytokines and chemokines without undue interference in coagulation (another cascade mediated by TF) creates the potential for a new class of biopharmaceuticals for improved treatment of serious diseases. In 2020, Exelixis, Inc. exercised their rights under a May 2019 option & license agreement with Iconic for their ICON-2 asset, a TF-targeting antibody drug conjugate, with potential broad impact in oncology. Exelixis has since moved the molecule (now known as XB002) into a large, Phase I clinical trial enrolling patients with advanced solid tumors ( ClinicalTrials.gov NCT04925284). Contacts